Lineage commitment and differentiation is driven by the concerted action of master transcriptional regulators at their target chromatin sites. Multiple efforts have characterized the key transcription factors (TFs) that determine the various hematopoietic lineages. However, the temporal interactions between individual TFs and their chromatin targets during differentiation and how these interactions dictate lineage commitment remains poorly understood. Here we perform…
Read More
Tuberculosis (TB) is the world’s second leading infectious disease killer after COVID-19. One-and-a-half million people died of the disease in 2020, there are cases in every country and age group, and drug resistance to TB is a public health crisis. Researchers from ISB’s Baliga Lab have developed algorithms to predict the efficacy of drugs in treating Mycobacterium tuberculosis (MTB), the causative agent for TB.…
Read More
When the worst pandemic of the century struck, a group of nine Seattle Children’s Research Institute’s scientists teamed up with researchers from Rockefeller University to innovate powerful tools for diagnosing and treating a virus that has claimed over 5 million lives. In a recent study published in E-life, scientists from Seattle Children’s Aitchison, Sather, Myler and Debley labs, in collaboration with Rockefeller University’s Chait, Rout and Bieniasz labs, demonstrate how…
Read More

Drug Delivery to the Central Nervous System

Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug development remains challenging, with high costs, long pathways to clinical use and high failure rates. The CNS is highly protected by physiological barriers, in particular, the blood–brain barrier and the blood–cerebrospinal fluid barrier, which limit access of most drugs. Biomaterials can be designed to bypass or traverse…
Read More
Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary software platform for biologics discovery, today announced the closing of a $18M Series B financing and acquisition of Orthogonal Biologics, a deep mutational scanning protein engineering spin-out from the University of Illinois at Urbana Champaign. The financing includes investments from OrbiMed Advisors, Trinity Ventures, Agent Capital, Yard Ventures, Washington Research…
Read More

Science Says: Fearless Science

Timid research doesn’t save lives. On Nov. 30, Fred Hutchinson Cancer Research Center brought several fearless scientists into conversation with the community in its latest Science Says virtual event. Trevor Noah, comedian and host of “The Daily Show,” talked with three Fred Hutch researchers working to end cancer and COVID-19. Noah’s interviews were followed by a special live Q&A led…
Read More
Men who inherit mutations in a gene called TP53 have a high risk of developing aggressive prostate cancer, a multicenter research team in the United States has found. The findings were reported in the journal European Urology. Researchers from more than a dozen institutions across the United States collaborated on the study. Dr. Kara N. Maxwell, assistant professor of medicine at the Perelman…
Read More
A new biotech startup with operations in Seattle and Durham, N.C., has launched with $40 million in new funding and a leadership team peppered with veterans of Seattle cell therapy biotechs. Tune Therapeutics is deploying technology to fine-tune the activity of genes in cells. The company has developed a proprietary platform called TEMPO that operates as an epigenomic therapy, according to a…
Read More
The UW Division of Nephrology is excited to welcome the 2022-23 incoming cohort of nephrology fellows! Drs. Lauren Haggerty, Jae Kim, Amruta Nair, Justin Bullock, and Anna Zemke will be joining the division. Justin Bullock (University of California San Francisco): Originally from Detroit, Michigan Justin completed his BS in chemical and biological engineering at MIT where he was two-time NCAA All-American…
Read More
The Fred Hutch/University of Washington Cancer Consortium has named Dr. Christopher Li its first associate director of Diversity, Equity and Inclusion. In this role, Li will coordinate and drive work that enhances diversity, equity and inclusion, or DEI, efforts across the Consortium’s partner institutions — Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, UW and Seattle Children’s. This work will enable…
Read More